Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.

MLA

Forbes, Lisa R., et al. “Jakinibs for the Treatment of Immune Dysregulation in Patients with Gain-of-Function Signal Transducer and Activator of Transcription 1 (STAT1) or STAT3 Mutations.” The Journal of Allergy and Clinical Immunology, vol. 142, no. 5, Nov. 2018, pp. 1665–69. EBSCOhost, https://doi.org/10.1016/j.jaci.2018.07.020.

APA

Forbes, L. R., Vogel, T. P., Cooper, M. A., Castro-Wagner, J., Schussler, E., Weinacht, K. G., Plant, A. S., Su, H. C., Allenspach, E. J., Slatter, M., Abinun, M., Lilic, D., Cunningham-Rundles, C., Eckstein, O., Olbrich, P., Guillerman, R. P., Patel, N. C., Demirdag, Y. Y., Zerbe, C., … Leiding, J. W. (2018). Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. The Journal of Allergy and Clinical Immunology, 142(5), 1665–1669. https://doi.org/10.1016/j.jaci.2018.07.020

Chicago

Forbes, Lisa R, Tiphanie P Vogel, Megan A Cooper, Johana Castro-Wagner, Edith Schussler, Katja G Weinacht, Ashley S Plant, et al. 2018. “Jakinibs for the Treatment of Immune Dysregulation in Patients with Gain-of-Function Signal Transducer and Activator of Transcription 1 (STAT1) or STAT3 Mutations.” The Journal of Allergy and Clinical Immunology 142 (5): 1665–69. doi:10.1016/j.jaci.2018.07.020.